Global Diabetic Neuropathy Market is valued USD 4680 million in 2016 is anticipated to grow USD 8460.3 billion with the compounded annual growth of 6.80% over the forecast period 2018-2025.

New York 16 Aug 2018, As per the new research study conducted by Bizwit Research & Consulting, Global Diabetic Neuropathy Market industry is poised to raise USD 8460.3 million by 2025. Diabetic Neuropathy is the damage caused to the nerve due to diabetes which often leads to pain and numbness in feet or lower legs. The pain can be experienced in other parts of the body such as hips, wrist and back depending upon the effect of neuropathy. There are different types of neuropathy such as focal neuropathy, proximal neuropathy, peripheral neuropathy and autonomic neuropathy. An estimated 50% of diabetic population suffers from diabetic neuropathy across the globe. Further, as per Reports estimates, 6-7 people per 1000 diabetic population suffer from diabetic neuropathy in the U.S. Rise in aging population coupled with rise in prevalence of diabetes, the patient pool for diabetic neuropathy will increase significantly, in turn fueling growth of the diabetic neuropathy market.

To view the summary or to request a sample copy of this report, please click the link mentioned below:

Global Diabetic Neuropathy Market Size study, by Types of Disorder (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), and by Regional Forecasts 2018-2025

The industry is seeming to be fairly competitive. Some of the leading market Pfizer, Inc, Johnson & Johnson, Boehringer Ingelheim GmbH., NeuroMetrix, Inc., Eli Lilly and Company, Astellas Pharma Inc, GlaxoSmithKline plc., Lupin Limited, Depomed, Inc., Glenmark Pharmaceuticals Ltd., Arbor Pharmaceuticals, LLC and so on. The fierce competitiveness has made these players spend in product developments to improve the customer’s requirements.

Key findings of the study:

  • North America is the largest market for diabetic neuropathy, with an estimated 35 million affected by the disease in U.S and Canada.
  • Asia Pacific region is fastest growing region with countries such as India and China showing lucrative growth. India has one of the highest rates of diabetes type 2 in the world.

 Bizwit Research & Consulting LLP has considered following segments for the study:

By Type of Disorder:

  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy

Regional Outlook:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Rest of the World

To get a sample of this report or to purchase a copy of the study, you can directly contact us. Or mail to us at: sales@bizwitresearch.com

how can we help you?

For any specific query or to receive regular updates of our latest titles fill the details on the contact form or in the subscription box down below. Trust us, we hate spams too. You will only get the regular updates and quality contents.

Loading…